Impact of Modeling & Simulation in Drug Development
Rosa’s Worldwide Webinar Series fosters the adoption of modeling and simulation by informing a broad audience about the strategic impact it can have on all aspects of research and development.
Since its inception in 2011, this complimentary monthly series has featured select speakers from academia, industry, Rosa client companies, and Rosa itself. The series has drawn many thousands of attendees worldwide from all drug development disciplines.
PLEASE NOTE - ***ALL WEBINARS PRIOR to 2017*** are available by contacting usCLICK HERE
Sign up to receive Webinar and QSP News Alerts
Date
Presenter / Topic
Register
Haojie Zhu, Professor of Pharmacy at the University of Michigan, College of Pharmacy
Haojie Zhu is a Professor in the Department of Clinical Pharmacy, University of Michigan College of Pharmacy. He graduated from China Pharmaceutical University with a major in Pharmacy and subsequently received his M.S. and Ph.D. in Pharmacology from the same University. He also holds an MBA degree from Nanjing University. He was a licensed Pharmacist as well as a trained Dentist in China. Dr. Zhu completed his postdoctoral training in pharmacogenomics and pharmacokinetics at the Medical University of South Carolina. His research focuses on identifying genetic variants and environmental regulators that impact the pharmacokinetics and pharmacodynamics of various therapeutic agents using an integrated multiomics approach (e.g., genomics, proteomics, and metabolomics) and machine learning. The generated information can be used to guide the personalized use of medications, maximizing efficacy while minimizing the risk of adverse effects.
AI-Driven Precision Medicine in Kidney Transplantation
Tomohiro Sasaki, PhD, Senior Manager, Otsuka Pharmaceutical Co.,Ltd., Osaka, Japan
Tomohiro Sasaki is a scientist with a main interest in pharmacometrics. He obtained his PhD in pharmaceutical sciences from Kyushu University (Fukuoka, Japan) in 2011. After working as a clinical pharmacologist in Nippon Boehringer Ingelheim, he joined Otsuka Pharmaceutical in 2015, where he is in charge of modeling & simulation work of several projects. He has experience in clinical pharmacology, pre-clinical, clinical PK/PD analysis, and modeling and simulation in various therapeutic areas.
QSP modeling of OPB-171775, a phosphodiesterase 3A–Schlafen 12 molecular glue, to predict clinical responses in patients with gastrointestinal stromal tumors
